Loading...
Loading...
Gracell Biotechnologies GRCL shares are trading higher Wednesday after Citigroup initiated coverage on the stock with a Buy rating and a price target of $35 per share.
Gracell Biotechnologies is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer.
Gracell Biotechnologies’s stock was up 7.63% at $27.94. The stock has a 52-week high of $28.88 and a 52-week low of $20.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in